Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance
- 1Division of Hematology and Oncology, Department of Medicine The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai New York New York USA
Abstract
Metastasis remains the leading cause of cancer‐related mortality. Even after major advances in early detection and systemic therapies, long‐term disease recurrence frequently arises from the presence of dormant disseminated tumor cells (DTCs) at distant sites. Dormant DTCs disseminate from the primary tumor and reside in secondary organs in a reversible quiescent state characterized by minimal proliferation, enabling resistance to therapies that target actively dividing cells. Despite their inactivity, dormant DTCs are far from inert. Dormant DTCs dynamically interact with the surrounding tumor microenvironment (TME), including stromal, vascular, and immune components, to establish niches that maintain quiescence while limiting immune detection. While the mechanisms by which proliferating cancer cells evade immune surveillance have been extensively studied, the processes governing immune regulation, immune‐mediated dormancy, and immune evasion of dormant DTCs remain incompletely integrated across literature. In this review, we explore recent advances describing how microenvironmental cues and immune pressures converge on tumor cell–intrinsic programs to sustain dormancy, promote immune tolerance, and enable long‐term survival of DTCs across different organs and cancer types. We further discuss conditions that disrupt this equilibrium and drive escape from dormancy, as well as emerging therapeutic strategies aimed at eliminating or controlling dormant DTCs by targeting dormancy‐specific immune and microenvironmental interactions.
Related
- Immune checkpoint blockade activates macrophages and remodels the lymph node microenvironment in melanoma metastasis
- Cardiac Metastasis From Lung Cancer: A Hidden Cardioembolic Source of Acute Ischemic Stroke
- Editorial: The insights of multi-omics into the microenvironment after tumor metastasis: a paradigm shift in molecular targeting modeling and immunotherapy for advanced cancer patients, volume II
- Proteomic Characterization of Prostate Cancer Bone Metastasis Subtypes Defines Progressive Remodeling States of the Bone-Tumor Microenvironment
- IGF2BP2 remodels the lung metastatic immune microenvironment to promote bladder cancer metastasis
BibTeX
@article{tiwary2026metastasis,
title = {{Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance}},
author = {Kanishka Tiwary and Jose Javier Bravo‐Cordero},
journal = {Molecular Oncology},
year = {2026},
month = nov,
doi = {10.1002/1878-0261.70259},
url = {https://doi.org/10.1002/1878-0261.70259},
note = {CC BY},
}
RIS
TY - JOUR
TI - Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance
AU - Kanishka Tiwary
AU - Jose Javier Bravo‐Cordero
PY - 2026
DA - 2026/11/04
JO - Molecular Oncology
DO - 10.1002/1878-0261.70259
UR - https://doi.org/10.1002/1878-0261.70259
AB - Metastasis remains the leading cause of cancer‐related mortality. Even after major advances in early detection and systemic therapies, long‐term disease recurrence frequently arises from the presence of dormant disseminated tumor cells (DTCs) at distant sites. Dormant DTCs disseminate from the primary tumor and reside in secondary organs in a reversible quiescent state characterized by minimal proliferation, enabling resistance to therapies that target actively dividing cells. Despite their inactivity, dormant DTCs are far from inert. Dormant DTCs dynamically interact with the surrounding tumor microenvironment (TME), including stromal, vascular, and immune components, to establish niches that maintain quiescence while limiting immune detection. While the mechanisms by which proliferating cancer cells evade immune surveillance have been extensively studied, the processes governing immune regulation, immune‐mediated dormancy, and immune evasion of dormant DTCs remain incompletely integrated across literature. In this review, we explore recent advances describing how microenvironmental cues and immune pressures converge on tumor cell–intrinsic programs to sustain dormancy, promote immune tolerance, and enable long‐term survival of DTCs across different organs and cancer types. We further discuss conditions that disrupt this equilibrium and drive escape from dormancy, as well as emerging therapeutic strategies aimed at eliminating or controlling dormant DTCs by targeting dormancy‐specific immune and microenvironmental interactions.
SN - 1878-0261
SN - 1574-7891
ER -